Search Results
Your search for The ASCO Post,The ASCO Post matches 16951 pages
Showing 751 - 800Racial Representation Affects Trust for Black Patients Seeking Prostate Cancer Information Online
Among Black patients with prostate cancer, racial representation may be a key factor affecting their trust in websites offering information on the disease, according to a recent study published by Loeb et al in The Journal of Urology. Background Black men may have higher rates of prostate cancer...
Triplet for Advanced HER2-Negative Breast Cancer
A novel three-drug combination achieved notable responses in patients with advanced HER2-negative breast cancer, according to new research published by Roussos Torres et al in Nature Cancer. The regimen included a histone deacetylase (HDAC) inhibitor combined with two types of checkpoint...
Understanding the Discordance About Prognosis Between Clinicians and Terminally Ill Patients and Their Surrogates
Research shows that about half of adults near the end of life in the United States are too ill to participate in decisions about whether to accept life-prolonging treatment,1 requiring family members and other proxies to serve as surrogate decision-makers for their critically ill loved ones....
Durvalumab Plus Ceralasertib in Patients With Immunotherapy-Resistant NSCLC
The combination of the anti–PD-L1 antibody durvalumab and the ATR kinase inhibitor ceralasertib may help overcome inherent immune resistance and reinvigorate antitumor activity in patients with advanced non–small cell lung cancer (NSCLC), according to a recent study published by Besse et al in...
Neoadjuvant Immunotherapy May Improve Long-Term Survival in Patients With Resectable Soft-Tissue Sarcoma
Patients with soft-tissue sarcoma treated with neoadjuvant immunotherapy had very little residual tumor at the time of surgery and promising long-term survival, according to phase II trial results published by Roland et al in Nature Cancer. Background About 13,000 new cases of soft-tissue...
FDA Approves Irinotecan Liposome as First-Line Treatment of Metastatic Pancreatic Adenocarcinoma
On February 13, the U.S. Food and Drug Administration (FDA) approved irinotecan liposome (Onivyde) with oxaliplatin, fluorouracil, and leucovorin for the first-line treatment of metastatic pancreatic adenocarcinoma. NAPOLI-3 Efficacy was evaluated in NAPOLI-3 (ClinicalTrials.gov identifier...
Plant-Based Diet May Be Linked to Improved Sexual Health in Men Treated for Prostate Cancer
Plant-based diets may be linked to a lower risk of erectile dysfunction, urinary incontinence, and other common side effects experienced by patients receiving treatment for prostate cancer, according to a new study published by Loeb et al in Cancer. The findings indicated that nutrition may lead to ...
Sleep Apnea May Be Prevalent Among Patients With Cancer at High Risk of Congestive Heart Failure
Sleep apnea may be prevalent among patients who are at higher risk of developing congestive heart failure from cancer therapy, according to new findings presented by Das et al at the American College of Cardiology (ACC) Advancing the Cardiovascular Care of the Oncology Patient course. Background...
Can Physical Activity Lessen Pain Intensity in Cancer Survivors?
Physical activity may help lessen the intensity of pain in cancer survivors, according to a recent study published by Swain et al in Cancer. Background Current U.S. guidelines regarding physical activity recommend that individuals receive 150 to 300 minutes of moderate-intensity exercise per week,...
Low-Dose Positron-Emission Mammography May Improve Breast Cancer Detection
Low-dose positron-emission mammography (PEM) may provide high sensitivity for detecting breast cancer and significantly reduce the likelihood of false-positive results, according to a recent study published by Freitas et al in Radiology: Imaging Cancer. The innovative breast imaging technique may...
Novel Biomarker in Cancer Survivors May Be Linked to Higher Risk of Mortality
Elevated N-terminal pro–brain natriuretic peptide (NT-proBNP) levels may be associated with a higher risk of mortality among cancer survivors, according to a recent study published by Cao et al in the Journal of the National Cancer Institute. NT-proBNP—produced in response to the stretching of...
Shedding Light on Mechanisms Behind Fulvestrant Resistance in Advanced ER-Positive Breast Cancer
Researchers may have uncovered the factors contributing to hormone therapy resistance in some patients with advanced estrogen receptor (ER)-positive breast cancer, according to a recent study published by Kingston et al in Cancer Discovery. The findings may indicate drugs currently in development...
Machine-Learning Model May Predict Oxaliplatin Benefit in Colon Cancer
The novel COLOXIS machine learning model may accurately predict which patients with colon cancer are most likely to derive benefit from oxaliplatin, according to a recent study published by Chen et al in the Journal of Clinical Oncology. The findings could ultimately allow physicians to better...
Ephrin B2 Identified as Potential Therapeutic Target to Inhibit Multiple Myeloma Growth
Researchers have discovered that the ephrin B2 protein may drive the growth and development of multiple myeloma and uncovered that blocking part of the protein’s unique signaling pathway may inhibit progression of the disease, according to a recent study published by Sasine et al in Cancer...
How ASCO’s Regional Councils Are Having an International Impact on Patients With Cancer
In September 2023, ASCO announced the establishment of its fourth regional council, the Central and Eastern European Regional Council, which includes representatives from 17 countries, with the goal of expanding ASCO’s mission globally to “conquer cancer through research, education, and promotion...
Fruquintinib Plus Paclitaxel as Second-Line Treatment for Gastric or Gastroesophageal Junction Cancer
The combination of fruquintinib and paclitaxel is a potential new second-line treatment for patients with advanced gastric or gastroesophageal junction cancer, according to data presented during the ASCO Plenary Series: February 2024 Session (Abstract 438780). Results of the phase III FRUTIGA...
Insufficiencies Discovered in Patient-Reported Outcomes Data From Genitourinary Cancer Clinical Trials
Investigators may have found a significant unmet need for improved analyses and reporting of patient-reported outcomes in genitourinary cancer clinical trials, according to a recent study published by Paravathaneni et al in eClinicalMedicine. Background Genitourinary cancers affect over 444,000...
High Reoperation Rates Following Breast-Conserving Surgery May Increase Cost of Care and Risk of Complications
Investigators have uncovered high rates of reoperation following initial breast-conserving surgery in patients with breast cancer that may contribute to increased costs of cancer care and a higher risk of postoperative complications, according to a recent study published by Kim et al in the Annals...
Andrea B. Apolo, MD, on Urothelial Carcinoma: Phase III Findings on Pembrolizumab vs Observation
Andrea B. Apolo, MD, of the National Cancer Institute, National Institutes of Health, discusses the results of the AMBASSADOR Alliance A031501 study, which showed adjuvant pembrolizumab improved disease-free survival vs observation for patients with high-risk muscle-invasive urothelial carcinoma...
Rohit K. Jain, MD, MPH, on Urothelial Carcinoma: New Data on Cabozantinib Plus Pembrolizumab
Rohit K. Jain, MD, MPH, of the H. Lee Moffitt Cancer Center and Research Institute, discusses a novel phase II trial of pembrolizumab plus cabozantinib. The study showed this combination may be efficacious as first-line therapy for patients with metastatic urothelial carcinoma, including those who...
Reflections on Cancer’s Toll on My Family
Over the past 2 years, my family and I have experienced firsthand the challenges of cancer. In the spring of 2021, my mother was diagnosed with stage IIB pancreatic cancer. She died in mid-2023 after developing metastatic disease, including peritoneal carcinomatosis. The experience has caused me to ...
Antihypertensive Drug Combinations May Help Reduce Blood Pressure in Patients Receiving Ibrutinib
Combination therapy with two or more antihypertensive drugs may reduce blood pressure in patients receiving ibrutinib, according to a recent study published by Samples et al in Blood Advances. Background Ibrutinib was the first Bruton tyrosine kinase (BTK) inhibitor to receive U.S. Food and Drug...
BTK Degrader May Target Treatment Resistance in Patients With CLL
Researchers have identified a next-generation Bruton’s tyrosine kinase (BTK) degrader that could help patients with chronic lymphocytic leukemia (CLL) and related hematologic malignancies overcome treatment resistance, according to a recent study published by Montoya et al in Science. The findings...
Bishoy M. Faltas, MD, on Upper Tract Urothelial Carcinoma: How Biology Shapes Therapy
Bishoy M. Faltas, MD, of Weill Cornell Medicine, discusses the biology of upper tract urothelial carcinoma and how it affects treatment, noting that most of these tumors are luminal papillary with a T-cell–depleted immune contexture driven by FGFR3 activation. Phase III trials have confirmed the...
Thomas Powles, MD, on Clear Cell Kidney Cancer: Overall Survival Update With Adjuvant Pembrolizumab
Thomas Powles, MD, of Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, and Queen Mary University of London, discusses overall survival results from the phase III KEYNOTE-564 study of adjuvant pembrolizumab vs placebo in patients with clear cell renal cell carcinoma...
Andrew Johns, MD, on Clear Cell Renal Cell Carcinoma: Data on Tivozanib in Pretreated Patients
Andrew Johns, MD, of The University of Texas MD Anderson Cancer Center, discusses efficacy, safety, and tolerability data on tivozanib. The agent yielded a modest clinical benefit in a minority of patients with advanced clear cell renal cell carcinoma who received prior immune checkpoint–based...
David H. Aggen, MD, PhD, on Advanced Bladder Cancer: HER2 and PD-L1 Immunohistochemistry and HER2 Genomic Alterations
David H. Aggen, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses reportedly the first data to describe an inverse correlation between HER2 immunohistochemistry expression and PD-L1 combined positive score. According to Dr. Aggen, these and other findings by his team may provide a...
Enrique Grande, MD, on Adrenocortical Carcinoma: Phase II Results on Cabozantinib Plus Atezolizumab
Enrique Grande, MD, of MD Anderson Cancer Center Madrid, discusses findings from the CABATEN/GETNE-T1914 study, in which cabozantinib plus atezolizumab showed modest activity in patients with locally advanced or metastatic adrenocortical carcinoma, a rare malignancy with a poor prognosis and...
Michiel S. Van Der Heijden, MD, PhD, on Metastatic Urothelial Carcinoma: Phase III Trial Data on Enfortumab Vedotin Plus Pembrolizumab vs Chemotherapy
Michiel S. Van Der Heijden, MD, PhD, of the Netherlands Cancer Institute, discusses phase III results from the global EV-302 study, showing that enfortumab vedotin-ejfv plus pembrolizumab improves outcomes in patients with previously untreated locally advanced metastatic urothelial carcinoma...
Cardio-Oncology Is a Growing Subspecialty, but Where Are the Oncologists?
It has been almost 20 years since the approval of trastuzumab for the treatment of early-stage, HER2-positive breast cancer. I remember returning from the 2005 ASCO Annual Meeting excited to offer patients a treatment that led to significant improvement in clinical outcomes. However, within a short ...
Global Cancer Burden May Be Growing Amidst Mounting Need for Cancer Services
The World Health Organization’s (WHO) cancer agency, the International Agency for Research on Cancer (IARC), has released updated findings of the current global burden of cancer alongside World Cancer Day on February 4, 2023. The WHO indicated that a majority of countries do not adequately finance...
Osimertinib May Offer Survival Benefit Over Immunotherapy in Some Patients With Unresectable NSCLC
Investigators have found that the targeted therapy osimertinib may be associated with improved progression-free survival when administered after chemotherapy and radiation in patients with non–small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations, according to a...
Sumanta K. Pal, MD, on Prostate Cancer: Impact of the Microbiome on Immune Therapy
Sumanta K. Pal, MD, of City of Hope, discusses the ways in which the composition of the gut microbiome may impact the outcome of immune therapy. Methods such as fecal microbiome transplant hold promise as a means of augmenting the effect of treatment and, according to Dr. Pal, potentially...
Saby George, MD, on Clear Cell Kidney Cancer: Subcutaneous vs Intravenous Nivolumab
Saby George, MD, of Roswell Park Comprehensive Cancer Center, discusses pharmacokinetics, efficacy, and safety results from CheckMate 67T, a phase III trial comparing the use of subcutaneous vs intravenous nivolumab in patients with advanced or metastatic clear cell renal cell carcinoma who have...
Umang Swami, MD, on Prostate Cancer: Differences in Genomic, Transcriptomic, and Immune Landscape Based on Site of Metastasis
Umang Swami, MD, of Huntsman Cancer Institute at the University of Utah, describes the molecular and immunologic mechanisms of metastatic tropism in advanced prostate cancer, data that may facilitate future drug development. In patients with metastatic disease, specific sites are associated with...
Syed Muneeb Alam, MD, on Urothelial Carcinoma: Microsatellite Instability and Response to Immune Checkpoint Blockade
Syed Muneeb Alam, MD, of Memorial Sloan Kettering Cancer Center, discusses study findings evaluating links among microsatellite instability status, tumor mutational burden, and response to immune checkpoint blockade in patients with microsatellite instability–high urothelial carcinoma (Abstract...
Sotorasib, the Poster Child for Project Optimus: Truths and Fantasies
In January 2021, two of us wrote in these pages about our field’s pressing need to pivot away from identifying and deploying the maximum tolerated dose (MTD) when it comes to targeted oncology therapies.1 We argued that, instead, one should be looking for the “optimal dose”—the dose that best...
Report Sheds Light on Critical Pathway Responsible for Treatment Resistance in Melanoma
Researchers may have uncovered a novel epigenetic pathway involved in the development of treatment resistance in melanoma and a chemical reagent that may be effective in resensitizing treatment-resistant tumors to targeted therapies, according to a recent study published by Wu et al in The Journal...
Blood Tests Could Help Predict Which Patients With Lymphoma May Respond Poorly to CAR T-Cell Therapy
Researchers may have uncovered a novel strategy to identify which patients may experience poorer outcomes from chimeric antigen receptor (CAR) T-cell therapy prior to treatment, according to a recent study published by Faramand et al in Blood Cancer Discovery. The findings indicate opportunities to ...
Reframing DCIS as an Opportunity for Cancer Prevention
We have been taught that early cancer detection and treatment save lives. The way to cure cancer is to find it early and treat it aggressively. The public has subscribed to this approach in our struggle to “eradicate cancer.” In certain disease types, there is merit to this philosophy. The ability...
Annual Increases in Cardiorespiratory Fitness May Help Reduce Risk of Prostate Cancer
An increase in annual cardiorespiratory fitness may be linked to a lower risk of developing prostate cancer, according to a recent study published by Bolam et al in the British Journal of Sports Medicine. Background There are relatively few known risk factors for prostate cancer. Although research...
UCHL1 Protein: Potential Biomarker and Therapeutic Target in Neuroendocrine Carcinomas and Neuroblastoma?
Investigators have found that the protein UCHL1 may be used as a molecular biomarker for diagnosing patients with highly aggressive neuroendocrine carcinomas and neuroblastoma and predicting and monitoring responses to therapy, according to a study published by Liu et al in Cell Reports Medicine....
Colon Cancer Mortality Rates: Predictions Across the European Union and United Kingdom
Investigators discovered that overweight and obesity may be contributing to rising rates of colon cancer mortality in younger patients, according to a recent study published by Santucci et al in the Annals of Oncology. The findings represent the first time colon cancer mortality rates among younger ...
Potential Risk Factors for Postoperative Venous Thromboembolism in Lung Cancer Identified
Postoperative pulmonary embolism may be predictive of increased 30-day mortality, reintubation, and readmission rates in patients with lung cancer, according to recent findings presented by Axtell et al at The Society of Thoracic Surgeons (STS) Annual Meeting. Background Patients with lung cancer...
Thomas Powles, MD, on RCC: Patient-Reported Outcomes With Belzutifan vs Everolimus
Thomas Powles, MD, of Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, and Queen Mary University of London, discusses outcomes reported by patients with previously treated renal cell carcinoma (RCC), taking part in the phase III LITESPARK-005 study. Belzutifan was...
Amanda Nizam, MD, on Urothelial Carcinoma: Study Results on Enfortumab Vedotin and Avelumab
Amanda Nizam, MD, of the Cleveland Clinic, discusses results from the UNITE study, which shows patients with advanced urothelial cancer who were treated with enfortumab vedotin-ejfv (EV) after switch maintenance avelumab had outcomes consistent with data with EV in platinum- and immune checkpoint...
Maha H.A. Hussain, MD, on Prostate Cancer: New Data on Abiraterone and Prednisone Plus Olaparib
Maha H.A. Hussain, MD, of the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, discusses phase II findings from the BRCAAway trial. This study showed that in patients with metastatic castration-resistant prostate cancer with BRCA1/2 or ATM alterations, abiraterone and...
UICC Offers Recommendations in Preparation for World Cancer Day 2024
The Union for International Cancer Control (UICC) has provided a new set of recommendations to eliminate inequities in cancer care in light of World Cancer Day on February 4, according to the new World Cancer Day 2024 Equity Report. Background Since its establishment in 2000, World Cancer Day has...
Use of Adjuvant Nivolumab in Patients With Muscle-Invasive Urothelial Carcinoma: CheckMate 274
Subsequent systemic therapy with the immune checkpoint inhibitor nivolumab may offer overall survival benefit in patients with muscle-invasive urothelial carcinoma who underwent surgery to remove their tumors, according to recent findings presented by Geynisman et al at the 2024 ASCO Genitourinary...
Immune Checkpoint Inhibitor–Based Therapy May Have Comparative Efficacy in Black and White Patients With Metastatic Renal Cell Carcinoma
Immune checkpoint inhibitor–based therapy may be an equally effective front-line treatment in both Black and White patients with metastatic renal cell carcinoma, according to recent findings presented by Kaur et al at the 2024 ASCO Genitourinary Cancers Symposium (Abstract 369). Background Race may ...
